# Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy

> **NCT00285051** · PHASE2 · TERMINATED · sponsor: **Rafa Laboratories** · enrollment: 6 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** inhaled delta-8-THC 300mcg or 600mcg per dose

## Key facts

- **NCT ID:** NCT00285051
- **Lead sponsor:** Rafa Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study drug expiry date not extended
- **Last updated:** 2020-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00285051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00285051, "Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00285051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*